Abbott’s ARCHITECT STAT High Sensitivity Troponin-I blood test received clearance from the U.S. Food and Drug Administration to help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women.

OncoCyte Corporation, a developer of novel tests for the early diagnosis and management of lung cancer, announced a definitive agreement to acquire Razor Genomics.